Jane Street Group, LLC Ngm Biopharmaceuticals Inc Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.17 - $1.92 $12,568 - $20,624	-10,742 Reduced 18.21%	48,238 $76,000
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $7,179 - $15,675	-11,966 Reduced 16.87%	58,980 $50,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $32,983 - $105,861	31,413 Added 79.46%	70,946 $75,000
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $62,915 - $116,806	-25,785 Reduced 39.48%	39,533 $102,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $124,969 - $181,407	33,594 Added 105.89%	65,318 $266,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $108,178 - $410,191	31,724 New	31,724 $159,000
Q1 2021 May 18, 2021	SELL	$24.99 - $31.93 $176,579 - $225,617	-7,066 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$16.21 - $31.44 $114,539 - $222,155	7,066 New	7,066 $214,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.